and inkjet printing [23, 24] AM processes have been leveraged to fabricate compartmentalized polypills, [28] oral drug delivery films, [30] patient-specific topical drug delivery systems, [31] stimuli-responsive pills, [32] nanomedicine containing pills, [33] and
Additive manufacturing (AM) appears poised to provide novel pharmaceutical technology and controlled release systems, yet understanding the effects of processing and post-processing operations on pill design, quality, and performance remains a significant barrier. This paper reports a study of the relationship between programmed concentration profile and resultant temporal release profile using a 3D printed polypill system consisting of a Food and Drug Administration (FDA) approved excipient (Pluronic F-127) and therapeutically relevant dosages of three commonly used oral agents for treatment of type 2 diabetes (300-500 mg per pill). A dual-extrusion hydrogel microextrusion process enables the programming of three unique concentration profiles, including core-shell, multilayer, and gradient structures. Experimental and computational studies of diffusive mass transfer processes reveal that programmed concentration profiles are dynamic throughout both pill 3D printing and solidification. Spectrophotometric assays show that the temporal release profiles could be selectively programmed to exhibit delayed, pulsed, or constant profiles over a 5 h release period by utilizing the core-shell, multilayer, and gradient distributions, respectively. Ultimately, this work provides new insights into the mass transfer processes that affect design, quality, and performance of spatially graded controlled release systems, as well as demonstrating the potential to create disease-specific polypill technology with programmable temporal release profiles.
Introduction
Although traditional processing operations, such as compaction and wet granulation, currently enable high-throughput www.advancedsciencenews.com www.advhealthmat.de polypills with orthogonal release profiles, [28, 34] demonstrating their promise for achieving increased tablet complexity, personalized care, and on-demand manufacturing. [20, 21, 26, 27, 35] For example, microextrusion printing was used to manufacture bilayer tablets that used diffusion and osmotic pressure to achieve zero-order and first-order release kinetics. [22] Microextrusion printing was also used to fabricate polypills containing up to five actives. [28] A low temperature fused filament fabrication method that reduced the risk of thermal degradation of the active ingredients was used for production of patient-specific rapid release pills. [25] In another example, a combination of 3D printing and casting was implemented to create pills with customizable release profiles. [36] However, although the aforementioned studies have established the initial body of knowledge in the area of 3D printed pharmaceuticals, various technical challenges and knowledge gaps exist, including techniques for online mixing of actives and understanding the effects of mass transfer throughout processing and postprocessing intervals on polypill design, performance, and quality.
Here, we provide a study of the relationship between programmed concentration profile and temporal release profile in 3D printed polypills using a combination of experimental and computational techniques. We show microextrusion 3D printing processes enable the fabrication of polypills containing up to three oral agents commonly used for treatment of type 2 diabetes (metformin hydrochloride, glyburide, and acarbose). Experimental measurements and finite element analysis (FEA) of diffusive mass transfer processes during both the processing and post-processing intervals revealed that the programmed concentration profiles were dynamic. The fabrication speed and solidification time were important process parameters that governed the difference between final and programmed concentration profiles. Drug release studies showed that the temporal release profile of individual actives from solid Pluronic F-127 polypills, a Food and Drug Administration (FDA) approved excipient, could be programmed ab initio to exhibit delayed, pulsed, and constant temporal profiles by changing the spatial concentration profiles among core-shell, multilayer, and gradient distributions, respectively. Ultimately, this work suggests that AM offers opportunities for designing patient and diseasespecific polypills with programmable temporal release profiles, and that internal mass transfer processes throughout processing and post-processing intervals are important considerations for polypill design, quality, and performance.
Results and Discussion

Dynamics of Programmed Concentration Profiles in 3D Printed Pills throughout Processing and Post-Processing Intervals
As shown schematically in Figure 1 , microextrusion 3D printing processes offer a unique opportunity to fabricate polypills and explore the effect of programmed concentration profiles (i.e., spatial distributions of actives) on temporal release profiles, as such is critical for manufacturing of quality "smart" pharmaceuticals. The premise for this study was that the temporal release profile of an active is governed by its programmed concentration profile, and that these concentration profiles are dynamic throughout both the processing and postprocessing intervals. Pluronic F-127 was selected as an excipient, also referred to as a bulking agent or diluent, based on its high yield stress at room temperature, which enables formation of free-standing hydrogel structures, [37] and it is FDA approved for use in food additives and pharmaceuticals. [38, 39] As shown schematically in the middle panel of Figure 1 , we examined three programmed spatial distributions of actives in the Pluronic F-127 pills, including core-shell, multilayer, and gradient structures. A dye-containing ink was used as a model active-containing ink given its similar molecular weight (MW) to the active species and ability to facilitate real-time measurement of the concentration profiles.
Photographs of the printed pills after the 90 min processing and 12 h post-processing intervals (i.e., the 3D printing and solidification intervals, respectively) are shown in Figure 2A ,B, respectively. Pills were printed at low speed to conduct real-time process monitoring for quality assurance. However, we found the print time could be reduced to ≈20 min using the same 3D printing system by increasing the feed rate. We note that the process is also scalable via the use of multiple extruders to enable multiplexing, and thus, improve throughput. Water loss during the solidification process resulted in a 13% and 30% decrease in pill's diameter and height, respectively (see Figure S1 of the Supporting Information). As shown in Figure 2A , the visible spatial distribution present immediately after 3D printing qualitatively matched the programmed distributions (i.e., the tool path described by G-code). Furthermore, the photographs shown in Figure 2B suggest that the programmed distributions persisted in the presence of pill shrinkage and solidification. We found that the solidified pills could be released www.advancedsciencenews.com www.advhealthmat.de from the glass substrates and withstand handling forces without fracture or disassembly (see Figure S2 of the Supporting Information). However, although the final distributions obtained after post-processing resembled the programmed concentration profiles, the data suggest that the programmed concentration profiles are dynamic throughout the processing and postprocessing intervals. In other words, the final concentration profiles do not match the programmed structures. To better understand the potential mechanisms that drive the dynamic behavior of programmed concentration profiles throughout both the processing and post-processing intervals, we next quantified the differences between the programmed distributions and those obtained following processing and post-processing. Figure 2C provides a quantitative measure of the radial concentration profile in the pills shown in Figure 2A ,B. As shown in Figure 2C , the final concentration profiles qualitatively matched the programmed distributions (i.e., tool path, here described by G-code), but were dynamic throughout the processing and post-processing intervals. As shown by comparing the final and programmed concentration profiles among each of the different spatial distributions, the core-shell and multilayer structures exhibited larger differences relative to the gradient structure. For example, the difference between the final and programmed normalized concentration at r = 0 mm was 0.4, 0.2, and 0.1 for the core-shell, multilayer, and gradient structures, respectively. The correlation between shape of the programmed profile and magnitude of change observed suggests diffusion processes may drive programmed concentration profile dynamics (i.e., large differences in concentration over short distances present in core-shell and multilayer structures establish relatively larger driving forces for diffusive mass transfer when compared with gradient structures). Thus, to better understand such potential mechanisms that drive the dynamics of programmed concentration profiles, we next examined how diffusive mass transfer processes affect the programmed concentration profiles throughout the processing interval.
Modeling of Mass Transfer Processes in 3D Printed Pharmaceuticals throughout the Processing Interval
To understand the mechanism driving the dynamics of programmed concentration profiles in the 3D printed pills, we next modeled the temporal evolution of the various spatial distributions in the pill throughout both the 3D printing (processing) and solidification (post-processing) intervals using a novel finite element model. Similar to modeling of heat transfer processes in fused filament fabrication AM processes, [40] modeling of mass transfer processes in microextrusion printing throughout the manufacturing interval is nontrivial due to the fact that the computational domain (i.e., size of the part) increases with time. We present here a model capable of calculating concentration profile dynamics in 3D printed parts across a computational domain that changes in size throughout the simulation. As shown schematically in Figure 3A , the computational domain extends in the print direction throughout the simulation interval based on the known speed of the 3D printing process [e.g., the linear speed or the time to print a single layer (t p,l )], here 10 mm s −1 and 90 s, respectively. Prior to examining the simulation results, it is useful to consider the potential role diffusive mass transfer processes may have considering both the pill design and the processing parameters. For example, it is possible to estimate the time scale for diffu-
/D, where L c is the characteristic length and D is the diffusion constant of an active species in a hydrogel. [41] Considering AM is a layer-by-layer fabrication process, L c may be approximated as the thickness of a single layer (250 µm). Thus, given D = 5 × 10 −11 m 2 s −1 , [49] the time scale for diffusion is 21 min (i.e., t d = 21 min). We remind the reader that the build time (t p ) was 90 min. Considering the ratio of the build time to the diffusive time scale (t p /t d ) is on the order of one (t p /t d = 90 min/21 min ≈ 4.3), diffusive mass transfer processes are likely to drive changes in programmed concentration profiles throughout the processing interval, such as those shown in Figure 2A ,C. Figure 3B ,C shows the final concentration profile in the 3D printed pills after the processing interval for each of the three spatial distributions: core-shell, multilayer, and gradient. The data show that diffusive mass transfer throughout the processing interval causes changes to each of the programmed concentration profiles. As shown in Figure 3B ,C, the largest differences between the final and programmed concentration profiles occurred in the core-shell and multilayer structures. The maximum differences occurred at the interface between domains of different concentration (denoted by positions h 1 and h 3 ). Such was also observed in the 3D printed pills from a top-down perspective shown in Figure 2 . Alternatively, as shown in the right panel of Figure 3B ,C, the pills with gradient structures exhibited relatively smaller deviations between final and programmed concentration profiles. For example, the maximum difference between the final and programmed concentration profile for the gradient structure was 4.3 mg mL −1 and was located at r = 0 mm near the bottom of the pill. The difference between the final and programmed concentration profiles was also a function of height, with relatively larger changes occurring toward the pill's base for all structures examined. This observation can be described by the longer time for diffusive mass transfer processes to affect initially printed layers.
Modeling of Mass Transfer Processes in 3D Printed Pharmaceuticals throughout the Post-Processing Interval
As previously shown in Figure 2 , a comparison of the pills before and after post-processing revealed that the concentration profiles were also dynamic throughout the solidification process. Thus, we next examined the temporal evolution of the programmed core-shell, multilayer, and gradient concentration profiles throughout the post-processing interval using the finite element model. As shown in Figure 4A ,B, the experimentally observed changes in programmed concentration profile can also be described by diffusion of actives between 3D printed layers under the driving force imposed by the concentration difference between the adjacent sub-domains (see Figure S3 of the Supporting Information for predicted concentration profiles in the r-h plane). This observation supports the hypothesis that the concentration difference between adjacent filaments (i.e., sub-domains) is an important consideration in predicting the deviation between programmed distributions and those obtained following post-processing. The data in Figure 4B show the largest differences between the final and programmed concentration profiles occurred at the center of the pill. To interpret the larger changes in concentration profile observed during the post-processing interval relative to the processing interval, it is useful to consider the ratios of the processing time (t p ) and postprocessing time (t pp ) to the diffusive time scale (t d ) (i.e., t p /t d and t pp /t d , respectively). For example, t p /t d = 90 min/21 min = 4.3 compared with t pp /t d = 720 min/21 min = 34.3, suggesting that diffusive mass transfer effects during the post-processing interval are larger than during the processing interval. We remind the reader that t d is actually time-dependent throughout the post-processing interval given the diffusivity decreases with time due to pill solidification (see the subsection "Finite Element Modeling of Diffusive Mass Transfer Processes during Processing and Post-processing Intervals" of the Experimental Section), yet the previous calculation provides a useful estimate for interpreting the observed concentration profile dynamics. Overall, the data shown in Figures 2-4 describe the mechanisms underlying changes in programmed concentration profiles throughout the processing and post-processing intervals, and demonstrate it is possible to achieve 3D printed pills with concentration profiles that exhibit core-shell, multilayer, and www.advancedsciencenews.com www.advhealthmat.de gradient structures. We next examined the temporal release profiles associated with the three spatial distributions using singleactive pill systems.
Measurement of Dissolution Kinetics
Prior to investigating the temporal release profiles for the three different spatial distributions, we first examined the dissolution kinetics of the solid Pluronic F-127 pills given the ratio of the diffusive time scale (t d ) to the dissolution time (t e ) serves as a useful measure of the time scale for drug release (i.e., the temporal release period). In this case, L c can be approximated as the radius of the pill (6.5 mm), since the case of drug release from the pill is now being considered as opposed to diffusion between adjacent layers as discussed in Figures 3 and 4 . Thus, given D = 5 × 10 −11 m 2 s −1 , the diffusive time scale (t d ) = 23.5 h. As shown in Figure 5A , the pill radius decreased throughout the dissolution process, over which the pill exhibited an interior solid domain surrounded by a thin gel layer. As shown by the trend in Figure 5B , the dissolution process at pH = 7 followed Higuchi-like kinetics, commonly associated with diffusiondriven release processes. [42] A change in the trend was observed approximately halfway through the dissolution process (t = 130 min) and corresponded to the onset of dissolution in the axial direction (see Figure 5A) , thereby accelerating the dissolution rate. We also found that the dissolution process in a low pH solution (pH = 3) exhibited similar kinetics (see Figure 5B ). Overall, the dissolution studies shown in Figure 5 suggest two important considerations when interpreting temporal release profiles: 1) the time scale of the temporal release period for the 3D printed Pluronic F-127 pills will be on the order of the dissolution time (t e , here 5 h), given it is smaller than the diffusive time scale (t d = 23.5 h), and 2) payload release by pill erosion (i.e., polymer gelation followed by dissolution into the liquid phase) drives the temporal release process. Having examined the pill dissolution kinetics, we next examined the temporal release profiles achieved by the three different spatial distributions.
Relationships between Programmed Concentration Profiles and Temporal Release Profiles in Single Active-Containing 3D Printed Pills
Although AM enables the integration of multiple actives within a single pill, also referred to as polypills, we first examined the temporal release profiles associated with pills that contain only a single active, here metformin hydrochloride, distributed in a core-shell, multilayer, or gradient structure (see Figure 6A) . The concentration of active in the metformin hydrochloride ink was selected based on the dynamic range of the spectroscopic assay used for quantification of drug release; however, we found metformin hydrochloride was printable at higher therapeutically relevant concentrations up to 300 mg mL −1 .
As shown in Figure 6 , the core-shell, multilayer, and gradient structures (i.e., programmed concentration profiles) exhibited unique temporal release profiles over the course of a 300 min release period. For example, as shown in Figure 6B , core-shell spatial distributions resulted in a delayed temporal release profile. The delayed temporal profile exhibited no release until 125 min, after which the total payload was released at a constant rate. Alternatively, the temporal release profile of the control pills that contained a uniform spatial distribution of metformin hydrochloride exhibited exponential release characteristics. As shown in Figure 6C , multilayer distributions resulted in a pulsed temporal release profile. The pulsed temporal release profile initially resembled that of control pill, but instead of continually increasing, the pulsed release profile plateaued at 65% payload release over the time range of 75-200 min. Following the plateau, a second exponential release phase was observed for the duration of the release period. As shown in Figure 6D , gradient distributions (here linear profiles) resulted in relatively constant temporal release profiles. Collectively, the results in Figure 6 show the ability to achieve programmable temporal release profiles of therapeutics from 3D printed pills containing a single active. A) Top-down micrographs of dissolving 3D printed Pluronic F-127 pills at various time points throughout the dissolution process (t = 0, 100, 200, and 300 min). B) Dissolution profile of the 3D printed Pluronic F-127 pills in DI water (n = 6 for pH = 7; n = 3 for pH = 3).
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Specifically, we found programmed concentration profiles with core-shell, multilayer, and gradient structures generate delayed, pulsed, and constant temporal release profiles, respectively.
Relationships between Programmed Concentration Profiles and Temporal Release Profiles in 3D Printed Polypills
Having demonstrated a correlation between programmed concentration profile and the resultant temporal release profile using single active-containing pills, we next examined the temporal release profiles achieved in polypills containing three commonly used oral agents for treatment of type 2 diabetes: metformin hydrochloride, acarbose, and glyburide. Treatment plans for type 2 diabetes commonly involve the aforementioned drugs administered by tablets containing dosages ranging from 1-1000 mg and release periods ranging from 1-8 h. [43, 44] Furthermore, research is ongoing regarding the use of drug combinations for treatment of type 2 diabetes, suggesting that polypill technology may play a role in future treatment plans. [45] The polypill design is shown in Figure 7A . The stacked polypill contained one layer with a core-shell spatial distribution of glyburide, a second layer with a multilayer distribution of acarbose, and a third layer with a gradient distribution of metformin hydrochloride. The polypill also had two end caps that contained no drug to decrease payload loss in the pill's axial direction. Similar to the studies using single active-containing metformin hydrochloride pills discussed in Figure 6 , the concentration of actives in the printed acarbose and glyburide inks were selected based on the dynamic range of the spectroscopic assays. The glyburide inks exhibited a higher yield stress and viscosity relative to the metformin hydrochloride and acarbose inks due to a larger amount of suspended solids based on the relatively lower solubility limit of glyburide in water. [46] Such behavior is consistent with previous observations from inks for nanocomposite printing that also exhibit yield stress increase due to increase in solid filler content. [47] The resultant temporal release profiles of the individual actives are shown in Figure 7B ,C.
Comparison of the temporal release profiles from the pills with single actives with those from the polypills (see Figures 6B-D and 7B-D, respectively) reveals that the correlations between spatial distribution and temporal release profile observed for the case of single active pills also hold for pills containing multiple actives. For example, as shown in Figure 7B -D, glyburide, acarbose, and metformin hydrochloride exhibited delayed, pulsed, and constant temporal release profiles, respectively. Specifically, as shown in Figure 7B , glyburide was not detected until 175 min, which compared reasonably to the value of 125 min observed for the metformin hydrochloride pills (see Figure 6B ). As shown in Figure 7C , acarbose exhibited a pulsed temporal release profile characterized by a plateau near 50% payload release over the time range of 125-225 min. The acarbose response also contained a short delay period not observed in the metformin hydrochloride pills shown in Figure 6C . Similar to the behavior observed in the single active pills, metformin hydrochloride was released from the polypills continuously over the 300 min release period; however, close inspection of the profile shows two separate intervals of differing release rates rather than a single interval as observed in the absence of other actives. We note that the polypills exhibited a higher relative standard deviation in temporal release profile compared with the pills that contained a single drug, but the origin cannot be elucidated at this time. Ultimately, these results suggest that it is possible to program the temporal release profiles of individual actives from polypills by controlling their concentration profiles. Specifically, we showed that programmed concentration profiles with core-shell, multilayer, and gradient structures can be used to produce delayed, pulsed, and constant temporal profiles, respectively. Overall, these results suggest unique opportunities for the design and manufacturing of patient and disease-specific polypills with programmable temporal release profiles. www.advancedsciencenews.com www.advhealthmat.de
Conclusions
Microextrusion 3D printing is a relatively new manufacturing process that is poised to address several of the current challenges in pharmaceutical tablet manufacturing. Here, we reported a study of the effect of programmed concentration profile on temporal release profile in Pluronic F-127 pills which contained up to three commonly prescribed oral agents used for treatment of type 2 diabetes. Programmed concentration profiles of varying spatial distribution were examined in this work, including core-shell, multilayer, and gradient structures. A combination of experimental studies and finite element models revealed programmed concentration profiles in 3D printed pills that are dynamic throughout both the 3D printing (processing) and solidification (post-processing) intervals. A novel finite element model revealed that the experimentally observed dynamics can be described by the diffusion of active species within the pill under driving forces imposed by the concentration gradient associated with a given spatial distribution. Temporal release studies showed that programmed concentration profiles with core-shell, multilayer, and gradient structures can be used to produce delayed, pulsed, and constant temporal release profiles, respectively. Overall, this work suggests unique opportunities for approaching the design and manufacturing of quality "smart" and personalized polypills with programmable temporal release profiles. In addition, this work suggests that the ability to understand mass transfer processes within pills during both processing and postprocessing intervals is critical toward design and quality control of future 3D printed pharmaceuticals.
Experimental Section
Materials: All materials were purchased from Sigma-Aldrich.
Preparation of Hydrogel Inks for Microextrusion 3D Printing: Inks were prepared in 30 wt% aqueous solutions of Pluronic F-127. In addition to a pure ink void of actives and a pure ink containing red dye, three active-containing inks were prepared and contained one of the following: 12.5 mg mL −1 metformin hydrochloride [molecular weight (MW) = 165.6 g mol −1 ]; 100 mg mL −1 glyburide (MW = 494.0 g mol −1 ), or 1 mg mL −1 acarbose (MW = 645.6 g mol −1 ). The concentrations of actives were selected based on the dynamic range of spectroscopic assays, but it was found that metformin hydrochloride and acarbose were also printable under similar conditions at higher therapeutically relevant concentrations of 300 and 100 mg mL −1 , respectively. The actives were first dissolved in deionized water (Direct-Q 3UV; EMD Millipore) at 4 °C, then mixed with Pluronic F-127, and subsequently stored overnight at 4 °C to dissolve the Pluronic F-127. The cold activecontaining polymer solutions were subsequently mixed using a centrifugal mixer (ARE-310; Thinky) for 30 s at 2000 rpm to ensure homogenization and uniformly suspend any undissolved solids, such as solid active particles in the case of supersaturated inks (i.e., those containing the active above its solubility limit as in the case of glyburide). This was followed by exposure to light vacuum for 10 min to remove air bubbles. The solutions were then loaded into different 55 mL syringe barrels and brought to room temperature to induce gelation.
Pill Design and 3D Printing: Cylindrical pills of radius and height equal to 6.5 and 10 mm, respectively, were fabricated using a custom microextrusion 3D printing system. [15, 48] The system was composed of a gantry robot (F5200N.1; Fisnar), multiple dispensing systems (Ultimus V; Nordson), and a desktop computer. Hydrogel inks were printed from 55 mL syringe barrels using 27 GA tapered tips (Nordson), except for glyburide inks, which were printed using 22 GA tapered tips (Nordson) to accommodate its relatively higher viscosity. A custom static mixing nozzle as reported earlier [48] was used for printing the gradient distributions. This nozzle enabled real-time mixing of two separate components, here one of the three drug-containing inks with the drug-free ink, such that the composition of the drug in the extruded ink could be varied between zero and the concentration of the drugcontaining ink by controlling the pressure applied to each syringe in real-time. Pills were printed at a linear velocity of 10 mm s −1 . A printing pressure of 12 psi was used for all pills except glyburide pills, which used a pressure of 8 psi, and gradient pills, which used pressures ranging from 38-46 psi. The build time (i.e., time to print one pill) was ≈90 min. Pills were solidified by drying under light vacuum for 12 h resulting in solid Pluronic F-127 pills.
All pills contained 2 mm thick top and bottom drug-free Pluronic F-127 caps to reduce the effect of axial losses during dissolution on the measured temporal release profile, thereby leaving a remaining 6 mm of the pill's center for active-containing material (schematically shown in Figure 1 ). This space contained one to three of the oral agents for type 2 diabetes (i.e., metformin hydrochloride, acarbose, and glyburide). Three experimental groups and one control group that consisted of the following programmed concentration profiles (i.e., spatial distributions of actives) were examined: core-shell, multilayer, gradient, and uniform distributions, respectively. The pills with core-shell distributions contained a 3 mm radius active-containing core surrounded by a drug-free shell from a radius of 3 mm to the pill boundary located at 6.5 mm. The pills with multilayer distributions contained a 2 mm radius active-containing core, surrounded by a drug-free band from a radius of 2-4.5 mm, and an active-containing shell from a radius of 4.5 mm to the pill boundary. The pills with gradient distributions contained a linearly decreasing concentration profile that changed from the maximum concentration of the ink at the center of the pill (r = 0) to a value of c = 0 at the pill boundary. The polypills contained a combination of the aforementioned spatial distributions with 2 mm sections along the axial direction dedicated to a different distribution. The pills with uniform distributions contained the same concentration of active at all positions.
Characterization of Concentration Profiles in 3D Printed Pills during Processing and Post-processing Intervals via Image Processing Techniques:
To both assess the time-varying concentration profiles of actives in printed pills and characterize the diffusion of active species within the 3D printing and solidification intervals (i.e., processing and post-processing intervals, respectively), pills described in the subsection "Pill Design and 3D Printing" were printed using red dye in place of the active. The drugfree caps were excluded to improve contrast for the active-containing region of the pill. Top-down photographs were then obtained (D7200; Nikon) yielding a 2D concentration profile. The concentration profiles were then analyzed using image processing software (ImageJ; National Institutes of Health). The images were first reduced to 8-bit grayscale, and the grayscale value (x) was then measured along the pill's radius. The grayscale value indicates the intensity of the dye at a given location, and therefore, the relative concentration of the dye. The normalized concentration profile (c/c max ) was then calculated as (x − x min )/ (x max − x min ), where x max and x min are the maximum and minimum greyscale values.
Pill Dissolution Studies: Measurements began by submerging solid pills in 30 mL of deionized (DI) water. Top-down brightfield micrographs were then taken at 10 min intervals for a duration of 300 min using a fluorescence stereoscope (AxioZoom; Zeiss). The pill radius was calculated as the average of the radius measured at the pill's top and bottom focal planes. Error bars correspond to the standard deviation of six repeated dissolution studies (n = 6).
Finite Element Modeling of Diffusive Mass Transfer Processes during Processing and Post-processing Intervals:
Given that the polypills contain adjacent internal domains of differing concentration, it was of interest to consider the diffusion of drugs within the pill during both the 3D printing process and the solidification process. Modeling of the diffusive mass transfer processes during both the processing and postprocessing intervals (i.e., 3D printing and solidification) was done using commercially available FEA software (v5.3; COMSOL Multiphysics). Mass transfer of actives within the pills was modeled using the Transport of Diluted Species module.
Mass Transfer during the Processing Interval: Modeling of active species transport within the 3D printed pill during fabrication requires solution of the diffusion equation across a computational domain that increases in size with time. The simulation began with the first printed layer. The initial concentration profile corresponded to one of the aforementioned spatial distributions of actives, which included core-shell, multilayer, or gradient structures. No flux boundary conditions were implemented at the borders of the pill and flux continuity boundary conditions were implemented at the interfaces between adjacent sub-domains of different concentrations. Calculations were done assuming Fickian diffusion and the diffusion constant (D 0 ) of the active in the printed Pluronic-127 gel inks was 5 × 10 −11 m 2 s −1
. [49] The computational domain was discretized using a physics-controlled mesh. The concentration profile was obtained by solving the governing equations at various mesh densities ranging from 937 to 1 293 947 elements over a time interval equal to the time to print a single layer (t p,1 ; here 1.5 min) using a time step of 0.01 min. The resulting concentration profile was then stored. Convergence was obtained at a mesh density of 238 832 elements within 1% of the previous mesh. Subsequently, the computational domain was extended vertically by the addition of another sub-domain to represent the addition of another printed layer of the pill. The governing equations were then solved across the new computational domain for a duration of t p subject to previously described boundary conditions but a modified initial condition that included both the previously stored solution as well as the programmed concentration profiles corresponding to one of the aforementioned spatial distributions of actives. This process was repeated n − 2 times, where n is the number of the printed layers (here n = 40). Upon addition of the final layer, the time interval of the simulation was then extended into a post-processing interval of duration greater than t p .
Mass Transfer during the Post-processing Interval: Modeling of active species transport within the 3D printed pill during solidification was done using the final computational domain and concentration profile obtained from the aforementioned simulation. The concentration profile within the pill during solidification was then calculated by solving the diffusion equation for an extended time period, t pp = 12 h, but with a time-dependent diffusion constant (D(t) = D 0 [1 − t/t pp ], where t is the time and t pp is the post-processing time, here a drying-based solidification process. This relation assumes the diffusion coefficient of a small molecule within a hydrogel decreases with decreasing hydration, [50] and diffusion within the solid phase is comparatively negligible. [51] Characterization of Temporal Release Profiles from 3D Printed Polypills: To begin experiments, the solidified pills were immersed in 20 mL of DI water. Small aliquots (volumes described below) were subsequently removed at 25 min intervals for a duration of 300 min. Briefly, to detect metformin hydrochloride, 50 µL of solution was removed at each time point and transferred to a well plate. To each well, 30 µL of 30% hydrogen peroxide and 140 µL of 5 m sodium hydroxide were added and the well plate was heated to 70 °C for 1 h. The absorbance peak at 400 nm was then measured. [52] To detect acarbose, 100 µL of solution was removed at each time point and transferred to a well plate. To each well, 100 µL of 0.5 m sodium hydroxide and 100 µL of 0.01 m potassium permanganate were added and allowed to react at room temperature for 30 min. The absorbance peak at 610 nm was then measured. [53] To detect glyburide, 30 µL of solution was removed at each time point and transferred to a well plate. To each well, 270 µL of dimethyl sulfoxide was added to dissolve the glyburide. The absorbance peak at 307 nm was then measured. [54] In the polypill experiments, separate aliquots for assay of each drug were removed at each time point to be tested. All measurements were conducted against a drug-free blank using a fluorescence microplate reader (Synergy H1M; BioTek). The fraction of active released was calculated as A(t)/A f where A(t) is the absorbance value measured at the wavelength of interest at time t and A f is the final absorbance measured after the pill dissolved. All assays were run in triplicate.
Statistical Analysis: Statistical analysis was conducted in OriginPro. All data are presented showing the mean value with error bars to one standard deviation. Sample size for pill dissolution was n = 6 (pH = 7) and n = 3 (pH = 3). Sample size for drug release profiles was n = 3 for each pill design. All normalized data were calculated using feature scaling.
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